{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:30:49Z","timestamp":1792783849949,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,5]],"date-time":"2018-04-05T00:00:00Z","timestamp":1522886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Amgen (Europe) GmbH"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.critrevonc.2018.03.021","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T18:46:51Z","timestamp":1522349211000},"page":"19-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Going the distance: Are we losing patients along the multiple myeloma treatment pathway?"],"prefix":"10.1016","volume":"126","author":[{"given":"Evangelos","family":"Terpos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Suzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2018.03.021_bib0005","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.clml.2017.05.003","article-title":"New agents in multiple myeloma: an examination of safety profiles","volume":"17","author":"Bringhen","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0010","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJMp1209034","article-title":"Drug policy for an aging population\u2014the European Medicines Agency\u2019s geriatric medicines strategy","volume":"367","author":"Cerreta","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0015","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.critrevonc.2017.11.016","article-title":"A question of class: treatment options for patients with relapsed and\/or refractory multiple myeloma","volume":"121","author":"Cook","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0020","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0030","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0035","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/bjh.14787","article-title":"Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth","volume":"178","author":"Dimopoulos","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0040","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0045","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/COC.0b013e3182a4676b","article-title":"Emerging therapies in multiple myeloma","volume":"38","author":"El-Amm","year":"2015","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0050","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","article-title":"Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores","volume":"101","author":"Engelhardt","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0055","series-title":"Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research 21st Annual Meeting","article-title":"Retrospective chart review study to evaluate the cost of care of patients with symptomatic multiple myeloma in France","author":"Gonzalez-McQuire","year":"2016"},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0060","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1182\/blood.V128.22.3607.3607","article-title":"Predictors of overall survival in patients with multiple myeloma initiating first- and second-line treatment in the Czech Republic","volume":"128","author":"H\u00e1jek","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0065","series-title":"Myeloma Frailty Score Calculator","author":"International Myeloma Working Group","year":"2018"},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0070","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.2011.044271","article-title":"Thalidomide versus dexamethasone for the treatment of relapsed and\/or refractory multiple myeloma: results from OPTIMUM, a randomized trial","volume":"97","author":"Kropff","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0075","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2017.0023","article-title":"Multiple myeloma, version 3.2017, NCCN Clinical Practice Guidelines in Oncology","volume":"15","author":"Kumar","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0080","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/joim.12590","article-title":"Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes","volume":"281","author":"Landgren","year":"2017","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0085","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/blood-2015-05-612960","article-title":"How I treat fragile myeloma patients","volume":"126","author":"Larocca","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0090","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0095","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0100","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1634\/theoncologist.2014-0042","article-title":"European perspective on multiple myeloma treatment strategies in 2014","volume":"19","author":"Ludwig","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0105","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 6","key":"10.1016\/j.critrevonc.2018.03.021_bib0110","doi-asserted-by":"crossref","first-page":"vi133","DOI":"10.1093\/annonc\/mdt297","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Moreau","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0115","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0120","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1182\/asheducation-2009.1.566","article-title":"How to treat elderly patients with multiple myeloma: combination of therapy or sequencing","author":"Palumbo","year":"2009","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0125","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0130","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clml.2011.11.001","article-title":"How to manage neutropenia in multiple myeloma","volume":"12","author":"Palumbo","year":"2012","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0135","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0140","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0145","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/cam4.1075","article-title":"Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States","volume":"6","author":"Qian","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0150","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/bjh.14193","article-title":"Multiple myeloma: practice patterns across Europe","volume":"175","author":"Raab","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0155","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0160","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0165","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2015-09-665018","article-title":"Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0170","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/S2352-3026(16)30147-8","article-title":"Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial","volume":"3","author":"San-Miguel","year":"2016","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0175","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol."},{"issue":"Mar. (8)","key":"10.1016\/j.critrevonc.2018.03.021_bib0180","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0185","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3324\/haematol.2014.117176","article-title":"European myeloma network guidelines for the management of multiple myeloma-related complications","volume":"100","author":"Terpos","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0190","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.03.021_bib0195","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br. J. Haematol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281730478X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084281730478X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T10:24:40Z","timestamp":1604053480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084281730478X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":39,"alternative-id":["S104084281730478X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.03.021","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Going the distance: Are we losing patients along the multiple myeloma treatment pathway?","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Amgen. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}